Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 975

1.

T serotyping of group a streptococcus isolated from patients with pharyngitis or streptococcal toxic shock syndrome in Japan between 2005 and 2017.

Ikebe T, Okuno R, Uchitani Y, Kanda Y, Sasaki M, Uchida K, Chiba K, Yamaguchi T, Otsuka H, Suzuki M, Ohya H, Watanabe H, Ohnishi M; Working Group for Beta-Hemolytic Streptococci in Japan.

J Infect Chemother. 2019 Nov 14. pii: S1341-321X(19)30327-7. doi: 10.1016/j.jiac.2019.10.010. [Epub ahead of print]

PMID:
31735631
2.

Surgical resection for persistent localized pulmonary fungal infection prior to allogeneic hematopoietic stem cell transplantation: Analysis of six cases.

Harada N, Kimura SI, Gomyo A, Hayakawa J, Tamaki M, Akahoshi Y, Ugai T, Kusuda M, Kameda K, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Sato M, Terasako-Saito K, Kikuchi M, Nakasone H, Kako S, Tsubochi H, Kanda Y.

J Infect Chemother. 2019 Nov 15. pii: S1341-321X(19)30237-5. doi: 10.1016/j.jiac.2019.08.003. [Epub ahead of print]

PMID:
31735628
3.

The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin.

Umino K, Hatano K, Ochi SI, Genda H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Yamamoto C, Ashizawa M, Sato K, Oh I, Fujiwara SI, Ohmine K, Muroi K, Kanda Y.

Int J Hematol. 2019 Nov 14. doi: 10.1007/s12185-019-02779-8. [Epub ahead of print]

PMID:
31728828
4.

Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age.

Kawamura K, Kanda J, Seo S, Kimura F, Hirayama M, Uchida N, Doki N, Fukuda T, Ozawa Y, Katayama Y, Takanashi M, Atsuta Y, Kanda Y.

Blood. 2019 Nov 13;134(Supplement_1):46. doi: 10.1182/blood-2019-125032.

PMID:
31723988
5.

Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.

Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, Tanaka M, Yuju O, Eto T, Ozawa Y, Takada S, Takanashi M, Kato K, Kanda Y, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Nov 9. pii: S1083-8791(19)30741-4. doi: 10.1016/j.bbmt.2019.11.001. [Epub ahead of print]

PMID:
31715305
6.

Increased CD83 expression of CD34-positive monocytes in donors during peripheral blood stem cell mobilization in humans.

Nakasone H, Kikuchi M, Kawamura K, Akahoshi Y, Sato M, Kawamura S, Yoshino N, Takeshita J, Yoshimura K, Misaki Y, Gomyo A, Tanihara A, Kusuda M, Tamaki M, Kimura SI, Kako S, Kanda Y.

Sci Rep. 2019 Nov 11;9(1):16499. doi: 10.1038/s41598-019-53020-9.

7.

Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-matched Allogeneic Transplantation: A Japanese National Registry Study.

Arima N, Kanda J, Yabe T, Morishima Y, Tanaka J, Kako S, Sakaguchi H, Kato M, Ohashi K, Ozawa Y, Fukuda T, Ota S, Tachibana T, Onizuka M, Ichinohe T, Atsuta Y, Kanda Y.

Biol Blood Marrow Transplant. 2019 Nov 5. pii: S1083-8791(19)30714-1. doi: 10.1016/j.bbmt.2019.10.032. [Epub ahead of print]

PMID:
31704471
8.

Broad-Spectrum Disease Resistance Conferred by the Overexpression of Rice RLCK BSR1 Results from an Enhanced Immune Response to Multiple MAMPs.

Kanda Y, Nakagawa H, Nishizawa Y, Kamakura T, Mori M.

Int J Mol Sci. 2019 Nov 6;20(22). pii: E5523. doi: 10.3390/ijms20225523.

9.

Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT.

Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, Tanihara A, Tamaki M, Kimura SI, Kako S, Kanda Y.

Blood Adv. 2019 Nov 12;3(21):3287-3296. doi: 10.1182/bloodadvances.2019000629.

10.

Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.

Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Mashima K, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Sugimoto M, Ishihara Y, Ashizawa M, Hatano K, Sato K, Oh I, Fujiwara SI, Ueda M, Ohmine K, Muroi K, Kanda Y.

Blood Adv. 2019 Nov 12;3(21):3266-3277. doi: 10.1182/bloodadvances.2019000745.

11.

Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.

Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H.

Hematol Oncol. 2019 Oct 31. doi: 10.1002/hon.2688. [Epub ahead of print]

PMID:
31674032
12.

Pharmacological β-adrenoceptor blockade can augment torsadogenic action of IKr inhibitor: Comparison of proarrhythmic effects of d-sotalol and dl-sotalol in the chronic atrioventricular block dogs.

Goto A, Hagiwara-Nagasawa M, Chiba K, Kambayashi R, Nunoi Y, Izumi-Nakaseko H, Matsumoto A, Kanda Y, Sugiyama A.

J Pharmacol Sci. 2019 Sep;141(1):86-89. doi: 10.1016/j.jphs.2019.09.009. Epub 2019 Sep 24.

13.

Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.

Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, Maeda T, Kato J, Ishiyama K, Matsuoka KI, Miyamoto T, Iida H, Ikegame K, Fukuda T, Ichinohe T, Atsuta Y, Mori T; Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Oct 13. pii: S1083-8791(19)30660-3. doi: 10.1016/j.bbmt.2019.10.004. [Epub ahead of print]

PMID:
31618688
14.

Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Yanada M, Konuma T, Yamasaki S, Kuwatsuka Y, Masuko M, Tanaka M, Ozawa Y, Toya T, Fukuda T, Ota S, Sawa M, Uchida N, Nakamae H, Eto T, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S.

Biol Blood Marrow Transplant. 2019 Oct 9. pii: S1083-8791(19)30656-1. doi: 10.1016/j.bbmt.2019.09.036. [Epub ahead of print]

PMID:
31605818
15.

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes.

Ribeiro AJS, Guth BD, Engwall M, Eldridge S, Foley CM, Guo L, Gintant G, Koerner J, Parish ST, Pierson JB, Brock M, Chaudhary KW, Kanda Y, Berridge B.

Front Pharmacol. 2019 Aug 29;10:934. doi: 10.3389/fphar.2019.00934. eCollection 2019. Review.

16.

Mutational Spectrum and Clinical Features of Patients with LOXHD1 Variants Identified in an 8074 Hearing Loss Patient Cohort.

Maekawa K, Nishio SY, Abe S, Goto SI, Honkura Y, Iwasaki S, Kanda Y, Kobayashi Y, Oka SI, Okami M, Oshikawa C, Sakuma N, Sano H, Shirakura M, Uehara N, Usami SI.

Genes (Basel). 2019 Sep 23;10(10). pii: E735. doi: 10.3390/genes10100735.

17.

Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis.

Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).

Bone Marrow Transplant. 2019 Sep 19. doi: 10.1038/s41409-019-0689-8. [Epub ahead of print] No abstract available.

PMID:
31537900
18.

A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort.

Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S.

Biol Blood Marrow Transplant. 2019 Sep 16. pii: S1083-8791(19)30627-5. doi: 10.1016/j.bbmt.2019.09.016. [Epub ahead of print]

PMID:
31536824
19.

A critical role of VMP1 in lipoprotein secretion.

Morishita H, Zhao YG, Tamura N, Nishimura T, Kanda Y, Sakamaki Y, Okazaki M, Li D, Mizushima N.

Elife. 2019 Sep 17;8. pii: e48834. doi: 10.7554/eLife.48834.

20.

Alloreactive T Cells Display a Distinct Chemokine Profile in Response to Conditioning in Xenogeneic GVHD Models.

Kawasaki Y, Sato K, Nakano H, Hayakawa H, Izawa J, Takayama N, Mashima K, Oh I, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Fujiwara SI, Ohmine K, Muroi K, Ito R, Hayakawa M, Ohmori T, Kanda Y.

Transplantation. 2019 Sep;103(9):1834-1843. doi: 10.1097/TP.0000000000002756.

PMID:
31461746
21.

Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis.

Minakata D, Fujiwara SI, Hayakawa J, Nakasone H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Ishihara Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y.

Acta Haematol. 2019 Aug 28:1-10. doi: 10.1159/000501818. [Epub ahead of print]

PMID:
31461700
22.

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.

Guth BD, Engwall M, Eldridge S, Foley CM, Guo L, Gintant G, Koerner J, Parish ST, Pierson JB, Ribeiro AJS, Zabka T, Chaudhary KW, Kanda Y, Berridge B.

Front Pharmacol. 2019 Aug 9;10:884. doi: 10.3389/fphar.2019.00884. eCollection 2019. Review.

23.

Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.

Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Date K, Nakajima N, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K.

Int J Hematol. 2019 Nov;110(5):566-574. doi: 10.1007/s12185-019-02720-z. Epub 2019 Aug 20.

PMID:
31432396
24.

Comprehensive analysis of syndromic hearing loss patients in Japan.

Ideura M, Nishio SY, Moteki H, Takumi Y, Miyagawa M, Sato T, Kobayashi Y, Ohyama K, Oda K, Matsui T, Ito T, Suzumura H, Nagai K, Izumi S, Nishiyama N, Komori M, Kumakawa K, Takeda H, Kishimoto Y, Iwasaki S, Furutate S, Ishikawa K, Fujioka M, Nakanishi H, Nakayama J, Horie R, Ohta Y, Naito Y, Kakudo M, Sakaguchi H, Kataoka Y, Sugahara K, Hato N, Nakagawa T, Tsuchihashi N, Kanda Y, Kihara C, Tono T, Miyanohara I, Ganaha A, Usami SI.

Sci Rep. 2019 Aug 19;9(1):11976. doi: 10.1038/s41598-019-47141-4.

25.

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, Fukuda T, Ozawa Y, Takahashi S, Onizuka M, Shiratori S, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Cancer Sci. 2019 Oct;110(10):3255-3266. doi: 10.1111/cas.14167. Epub 2019 Aug 29.

26.

Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation.

Kawase T, Tanaka H, Kojima H, Uchida N, Ohashi K, Fukuda T, Ozawa Y, Ikegame K, Eto T, Mori T, Miyamoto T, Hidaka M, Shiratori S, Takanashi M, Atsuta Y, Ichinohe T, Kanda Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Aug 7. pii: S1083-8791(19)30514-2. doi: 10.1016/j.bbmt.2019.07.042. [Epub ahead of print]

PMID:
31400501
27.

Retinoic acid promotes barrier functions in human iPSC-derived intestinal epithelial monolayers.

Yamada S, Kanda Y.

J Pharmacol Sci. 2019 Aug;140(4):337-344. doi: 10.1016/j.jphs.2019.06.012. Epub 2019 Jul 26.

28.

Updated Clinical Outcomes of Hematopoietic Stem Cell Transplantation Using Myeloablative Total Body Irradiation with Ovarian Shielding to Preserve Fertility.

Ashizawa M, Akahoshi Y, Nakano H, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, Tamaki M, Kusuda M, Kameda K, Wada H, Kawamura K, Sato M, Terasako-Saito K, Tanihara A, Kimura SI, Nakasone H, Kako S, Akahane K, Wakatsuki M, Shirai K, Kanda Y.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30511-7. doi: 10.1016/j.bbmt.2019.07.039. [Epub ahead of print]

PMID:
31394267
29.

Analysis of electro-mechanical relationship in human iPS cell-derived cardiomyocytes sheets under proarrhythmic condition assessed by simultaneous field potential and motion vector recordings.

Sugiyama A, Hagiwara-Nagasawa M, Kambayashi R, Goto A, Chiba K, Naito AT, Kanda Y, Matsumoto A, Izumi-Nakaseko H.

J Pharmacol Sci. 2019 Aug;140(4):317-320. doi: 10.1016/j.jphs.2019.07.006. Epub 2019 Jul 19.

30.

Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis.

Haraguchi M, Miuma S, Masumoto H, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Miyaaki H, Taura N, Nakao K.

Hepatol Int. 2019 Jul;13(4):482-489. doi: 10.1007/s12072-019-09963-2. Epub 2019 Jul 9.

PMID:
31290070
31.

Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.

Izumi-Nakaseko H, Fujiyoshi M, Hagiwara-Nagasawa M, Goto A, Chiba K, Kambayashi R, Naito AT, Ando K, Kanda Y, Ishii I, Sugiyama A.

Cardiovasc Toxicol. 2019 Jul 6. doi: 10.1007/s12012-019-09538-5. [Epub ahead of print]

PMID:
31280457
32.

Systematic expression analysis of genes related to generation of action potentials in human iPS cell-derived cardiomyocytes.

Kodama M, Furutani K, Kimura R, Ando T, Sakamoto K, Nagamori S, Ashihara T, Kurachi Y, Sekino Y, Furukawa T, Kanda Y, Kurokawa J.

J Pharmacol Sci. 2019 Aug;140(4):325-330. doi: 10.1016/j.jphs.2019.06.006. Epub 2019 Jun 21.

33.

Cardiotoxicity assessment of drugs using human iPS cell-derived cardiomyocytes: From proarrhythmia risk to cardiooncology.

Satsuka A, Kanda Y.

Curr Pharm Biotechnol. 2019 Jun 28. doi: 10.2174/1389201020666190628143345. [Epub ahead of print]

PMID:
31264543
34.

Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.

Umino K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y.

Ann Hematol. 2019 Sep;98(9):2121-2129. doi: 10.1007/s00277-019-03738-3. Epub 2019 Jun 25.

PMID:
31240469
35.

Depolysulfidation of Drp1 induced by low-dose methylmercury exposure increases cardiac vulnerability to hemodynamic overload.

Nishimura A, Shimoda K, Tanaka T, Toyama T, Nishiyama K, Shinkai Y, Numaga-Tomita T, Yamazaki D, Kanda Y, Akaike T, Kumagai Y, Nishida M.

Sci Signal. 2019 Jun 25;12(587). pii: eaaw1920. doi: 10.1126/scisignal.aaw1920.

PMID:
31239323
36.

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.

Yamashita Y, Tanaka KI, Yamakawa N, Asano T, Kanda Y, Takafuji A, Kawahara M, Takenaga M, Fukunishi Y, Mizushima T.

Bioorg Med Chem. 2019 Aug 1;27(15):3339-3346. doi: 10.1016/j.bmc.2019.06.016. Epub 2019 Jun 8.

PMID:
31204225
37.

Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant.

Shimizu H, Doki N, Kanamori H, Sakura T, Mori T, Machida S, Takahashi S, Ohwada C, Fujisawa S, Yano S, Hagihara M, Kanda Y, Onoda M, Gotoh M, Kako S, Taguchi J, Usuki K, Kawai N, Aotsuka N, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).

Bone Marrow Transplant. 2019 Jun 11. doi: 10.1038/s41409-019-0585-2. [Epub ahead of print]

PMID:
31186516
38.

Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.

Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study; Group for Cell Therapy (KSGCT).

Leukemia. 2019 Nov;33(11):2610-2618. doi: 10.1038/s41375-019-0494-9. Epub 2019 May 30.

PMID:
31147621
39.

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1890-1897. doi: 10.1016/j.bbmt.2019.05.021. Epub 2019 May 25.

PMID:
31136799
40.

Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life.

Kurosawa S, Yamaguchi T, Oshima K, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Kohno A, Miyamura K, Umemoto Y, Teshima T, Taniguchi S, Yamashita T, Inamoto Y, Kanda Y, Okamoto S, Atsuta Y.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1851-1858. doi: 10.1016/j.bbmt.2019.05.016. Epub 2019 May 24.

PMID:
31129353
41.

OTOF mutation analysis with massively parallel DNA sequencing in 2,265 Japanese sensorineural hearing loss patients.

Iwasa YI, Nishio SY, Sugaya A, Kataoka Y, Kanda Y, Taniguchi M, Nagai K, Naito Y, Ikezono T, Horie R, Sakurai Y, Matsuoka R, Takeda H, Abe S, Kihara C, Ishino T, Morita SY, Iwasaki S, Takahashi M, Ito T, Arai Y, Usami SI.

PLoS One. 2019 May 16;14(5):e0215932. doi: 10.1371/journal.pone.0215932. eCollection 2019.

42.

A consideration for efficient unrelated hematopoietic stem cell source acquisition-from an experience of Japan.

Nishiwaki S, Miyamura K, Kanda Y, Takanashi M, Uchida N, Fukuda T, Ikegame K, Ohashi K, Eto T, Ozawa Y, Shiratori S, Iwato K, Matsuoka KI, Hidaka M, Ichinohe T, Atsuta Y, Kodera Y, Okamoto S.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0542-0. [Epub ahead of print] No abstract available.

PMID:
31089273
43.

Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience.

Yanada M, Konuma T, Kuwatsuka Y, Kondo T, Kawata T, Takahashi S, Uchida N, Miyakoshi S, Tanaka M, Ozawa Y, Sawa M, Nakamae H, Aotsuka N, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S.

Bone Marrow Transplant. 2019 Nov;54(11):1789-1798. doi: 10.1038/s41409-019-0539-8. Epub 2019 May 8.

PMID:
31068659
44.

Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease.

Yamasaki S, Aoki J, Mori J, Mizuno S, Uchida N, Ohashi K, Fukuda T, Ikegame K, Eto T, Ogawa Y, Tanaka M, Hidaka M, Iwato K, Sawa M, Ichinohe T, Kanda Y, Atsuta Y, Yanada M, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Bone Marrow Transplant. 2019 Apr 10. doi: 10.1038/s41409-019-0527-z. [Epub ahead of print] No abstract available.

PMID:
30971777
45.

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia.

Mori T, Onishi Y, Ozawa Y, Kato C, Kai T, Kanda Y, Kurokawa M, Tanaka M, Ashida T, Sawayama Y, Fukuda T, Ichinohe T, Atsuta Y, Yamazaki H.

Int J Hematol. 2019 Jun;109(6):711-717. doi: 10.1007/s12185-019-02644-8. Epub 2019 Apr 8.

PMID:
30963471
46.

Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.

Umino K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y.

Leuk Lymphoma. 2019 Aug;60(8):1926-1933. doi: 10.1080/10428194.2018.1564824. Epub 2019 Apr 5.

PMID:
30947577
47.

Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.

Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K.

Br J Haematol. 2019 Jul;186(1):86-90. doi: 10.1111/bjh.15898. Epub 2019 Apr 2.

PMID:
30941758
48.

Cryoprotectant-free cryopreservation of mammalian cells by superflash freezing.

Akiyama Y, Shinose M, Watanabe H, Yamada S, Kanda Y.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7738-7743. doi: 10.1073/pnas.1808645116. Epub 2019 Apr 1.

49.

Multiple myeloma derived from a kidney transplant donor who also developed myeloma after kidney donation.

Fujiwara SI, Ikeda T, Morita K, Shinzato T, Ishikawa N, Nakamura N, Yagisawa T, Kanda Y.

Am J Transplant. 2019 Aug;19(8):2374-2377. doi: 10.1111/ajt.15373. Epub 2019 Apr 19.

PMID:
30916888
50.

Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT.

Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, Iwato K, Uchida N, Eto T, Ashida T, Mori T, Sawa M, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Int J Hematol. 2019 Jun;109(6):684-693. doi: 10.1007/s12185-019-02631-z. Epub 2019 Mar 15.

PMID:
30877606

Supplemental Content

Support Center